nimotuzumab,dostarlimab
gsk,daiichi sankyo,biocon,oncoscience
['dostarlimab', 'nimotuzumab', 'pancreatic', 'rectal']
4. dostarlimab in rectal- intriguing. long term data needed. even then, surgery will be cost effective in most countries. 5. nimotuzumab in pancreatic- could be a very effective and cost-effective alternative to abraxane as a combo partner with gem 2/
Personal account. Med Onc. Associate Professor @queensoncology @QueensuPHS. #cancerpolicy #globaloncology #cancergroundshot. Pubs-https://t.co/DE00s50Vpj